[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 1974

Plasminogen in the Prevention of Hyaline Membrane Disease

Author Affiliations

From the departments of pediatrics (Drs. C. Ambrus, Weintraub, Choi, Eisenberg, and Staub), obstetrics and gynecology (Drs. Courey, Foote, Goplerud, Moesch, and Ray), and internal medicine (Dr. J. Ambrus), State University of New York at Buffalo; and the Roswell Park Memorial Institute (Drs. Ambrus, Bross, and Ambrus, and Messrs. Jung and Mink), Buffalo.

Am J Dis Child. 1974;127(2):189-194. doi:10.1001/archpedi.1974.02110210039005

Alveolar hyaline membranes in hyaline membrane disease (HMD) consist partly of fibrin. Premature infants lack serum plasminogen, thus they are unable to develop effective fibrinolysis and are defenseless against fibrin deposition. Therefore, plasminogen was tested for the prevention of HMD.

In a double-blind randomized study, 100 infants between 1.0 and 2.5 kg birthweight received plasminogen or placebo soon after birth. Factors placing the infant at risk from HMD were found to be evenly divided between control and treated groups.

Among the 51 infants who received placebo, seven developed mild, and ten developed severe respiratory distress; of these ten, five died with HMD. Two infants died from causes other than HMD.

Among the 49 infants treated with plasminogen, 13 developed mild and three developed severe respiratory distress. There was no death due to HMD. Two deaths were due to other causes.